James S. Ely III - 30 Jun 2026 Form 4 Insider Report for SELECT MEDICAL HOLDINGS CORP (SEM)

Reporting relationship: Director
Issuer ticker: SEM
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2026, 14:22:14 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ John F. Duggan, Attorney-in-Fact

Key filing fact

James S. Ely III filed Form 4 for SELECT MEDICAL HOLDINGS CORP (SEM) on 01 Jul 2026.

Key facts

This page summarizes James S. Ely III's Form 4 filing for SELECT MEDICAL HOLDINGS CORP (SEM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 14:22.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001463791 Primary reporting owner

Ely James S. III

Relationship: Director
Address: C/O SELECT MEDICAL HOLDINGS CORPORATION, 4714 GETTYSBURG ROAD, MECHANICSBURG
Signature: /s/ John F. Duggan, Attorney-in-Fact
Signature date: 01 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SEM transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -161,674
Change %: -100%
Price: $16.50^*
Shares after: 0
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

James S. Ely III is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on March 2, 2026, by and among the Issuer, Stallion Intermediate Corporation, and Stallion MergerSub Corporation (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on March 3, 2026). At the effective time of the merger, each of the Reporting Person's shares of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $16.50 per share in cash without interest ("Merger Consideration").

Footnote F2

Includes unvested shares of Company common stock subject to forfeiture conditions (the "Company Restricted Shares"). Pursuant the Merger Agreement, each Company Restricted Share held by the Reporting Person that was outstanding immediately prior to the effective time vested in full as of immediately prior to the effective time of the merger and was automatically converted into the right to receive the Merger Consideration, less any applicable tax withholdings.